Physician profile
Freida D Lambert
NPI 1962854216
$1,475.37
in general payments reported to CMS, 2019-2025
14 companies · $31.89 in 2025
The $31.89 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $489 · 2022: $382 · 2023: $404 · 2024: $168 · 2025: $31.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $327.95 | 2021-2024 | Farxiga, Airsupra |
| Novo Nordisk INC | $231.20 | 2021-2024 | Ozempic, Rybelsus, Tresiba |
| Abbvie INC. | $222.86 | 2021-2025 | |
| Glaxosmithkline, LLC. | $212.89 | 2022-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $133.85 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $121.94 | 2022-2023 | Quviviq |
| Amarin Pharma, INC. | $83.73 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.81 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.88 | 2022 | |
| Pfizer INC. | $20.80 | 2021 | |
| Abbott Laboratories | $18.27 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.54 | 2025 | Caplyta |
| Genentech USA, INC. | $14.25 | 2021 | |
| Esperion Therapeutics, INC. | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Freida Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.